{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:42:18Z","timestamp":1787020938704,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["R01LM012806"],"award-info":[{"award-number":["R01LM012806"]}]},{"DOI":"10.13039\/100004917","name":"CPRIT","doi-asserted-by":"crossref","award":["RP180734"],"award-info":[{"award-number":["RP180734"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MD Anderson B-cell Lymphoma Moon Shot Project"},{"name":"The Gary Rogers Foundation"},{"name":"Kinder Foundation"},{"DOI":"10.13039\/100001064","name":"Cullen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001064","id-type":"DOI","asserted-by":"publisher"}]},{"name":"start-up research funds by MD Anderson Cancer Center"},{"name":"NIH-funded Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]},{"name":"NIH Core Grant for the Sequencing and Microarray Facility","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Brexucabtagene autoleucel CAR-T therapy is highly efficacious in overcoming resistance to Bruton\u2019s tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma. However, many patients relapse post CAR-T therapy with dismal outcomes. To dissect the underlying mechanisms of sequential resistance to BTKi and CAR-T therapy, we performed single-cell RNA sequencing analysis for 66 samples from 25 patients treated with BTKi and\/or CAR-T therapy and conducted in-depth bioinformatics\u2122 analysis. Our analysis revealed that MYC activity progressively increased with sequential resistance.\n                    <jats:italic>HSP90AB1<\/jats:italic>\n                    (Heat shock protein 90 alpha family class B member 1), a MYC target, was identified as early driver of CAR-T resistance.\n                    <jats:italic>CDK9<\/jats:italic>\n                    (Cyclin-dependent kinase 9), another MYC target, was significantly upregulated in Dual-R samples. Both\n                    <jats:italic>HSP90AB1<\/jats:italic>\n                    and\n                    <jats:italic>CDK9<\/jats:italic>\n                    expression were correlated with MYC activity levels. Pharmaceutical co-targeting of HSP90 and CDK9 synergistically diminished MYC activity, leading to potent anti-MCL activity. Collectively, our study revealed that HSP90-MYC-CDK9 network is the primary driving force of therapeutic resistance.\n                  <\/jats:p>","DOI":"10.1186\/s40164-024-00484-9","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T05:02:54Z","timestamp":1707282174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma"],"prefix":"10.1186","volume":"13","author":[{"given":"Fangfang","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovanny","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Huan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JohnNelson R.","family":"Bigcal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Badillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra","family":"Meena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas M.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"issue":"5","key":"484_CR1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97(5):638\u201356.","journal-title":"Am J Hematol"},{"issue":"6","key":"484_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med"},{"issue":"10121","key":"484_CR3","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659\u201367.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"484_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1182\/blood-2018-99-117956","volume":"132","author":"YQ Song","year":"2018","unstructured":"Song YQ, Zhou KS, Zou DH, Zhou JF, Hu JD, Yang HY, et al. Safety and activity of the investigational Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma from a phase 2 trial. Blood. 2018;132(Suppl 1):148.","journal-title":"Blood"},{"issue":"14","key":"484_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"6","key":"484_CR6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","volume":"26","author":"CY Cheah","year":"2015","unstructured":"Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175\u20139.","journal-title":"Ann Oncol"},{"issue":"2","key":"484_CR7","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1111\/bjh.17197","volume":"192","author":"P Jain","year":"2021","unstructured":"Jain P, Nastoupil L, Westin J, Lee HJ, Navsaria L, Steiner RE, et al. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol. 2021;192(2):e38\u201342.","journal-title":"Br J Haematol"},{"issue":"12","key":"484_CR8","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.3390\/cancers11121834","volume":"11","author":"B Pula","year":"2019","unstructured":"Pula B, Golos A, Gorniak P, Jamroziak K. Overcoming ibrutinib resistance in chronic lymphocytic leukemia. Cancers (Basel). 2019;11(12):1834.","journal-title":"Cancers (Basel)"},{"issue":"Suppl 1","key":"484_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood-2019-125934","volume":"134","author":"L Zhang","year":"2019","unstructured":"Zhang L, Guo H, Zhang H, Yao YX, Liu Y, Zhang SJ, et al. Genetically defined metabolic targets overcome ibrutinib resistance in mantle cell lymphoma. Blood. 2019;134(Suppl 1):395.","journal-title":"Blood"},{"key":"484_CR10","doi-asserted-by":"publisher","first-page":"14920","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920.","journal-title":"Nat Commun"},{"key":"484_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1126\/scitranslmed.aau1167","volume":"11","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019;11:491.","journal-title":"Sci Transl Med."},{"issue":"1","key":"484_CR12","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1038\/s41467-021-22872-z","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, et al. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun. 2021;12(1):2877.","journal-title":"Nat Commun"},{"key":"484_CR13","doi-asserted-by":"publisher","first-page":"14049","DOI":"10.1038\/ncomms14049","volume":"8","author":"GX Zheng","year":"2017","unstructured":"Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049.","journal-title":"Nat Commun"},{"issue":"13","key":"484_CR14","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck Iii WM, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573\u201387.","journal-title":"Cell"},{"issue":"7","key":"484_CR15","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888\u2013902.","journal-title":"Cell"},{"key":"484_CR16","unstructured":"Tickle TI, Georgescu C, Brown M, Haas B. inferCNV of the Trinity CTAT Project. https:\/\/github.com\/broadinstitute\/inferCNV2019."},{"issue":"1","key":"484_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57(1):289\u2013300.","journal-title":"J R Stat Soc"},{"issue":"W1","key":"484_CR18","doi-asserted-by":"publisher","first-page":"W199","DOI":"10.1093\/nar\/gkz401","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019;47(W1):W199\u2013205.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"484_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol."},{"issue":"7745","key":"484_CR20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-019-0969-x","volume":"566","author":"J Cao","year":"2019","unstructured":"Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ, et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature. 2019;566(7745):496\u2013502.","journal-title":"Nature"},{"issue":"1","key":"484_CR21","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s41467-020-14766-3","volume":"11","author":"K van den Berge","year":"2020","unstructured":"van den Berge K, de B\u00e9zieux H, Street K, Saelens W, Cannoodt R, Saeys Y, et al. Trajectory-based differential expression analysis for single-cell sequencing data. Nat Commun. 2020;11(1):1201.","journal-title":"Nat Commun."},{"issue":"3","key":"484_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1006701","volume":"15","author":"M Mounir","year":"2019","unstructured":"Mounir M, Lucchetta M, Silva TC, Olsen C, Bontempi G, Chen X, et al. New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx. PLoS Comput Biol. 2019;15(3): e1006701.","journal-title":"PLoS Comput Biol"},{"key":"484_CR23","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1101\/gr.275193.120","volume":"31","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Park C, Bennett C, Thornton M, Kim D. Rapid and accurate alignment of nucleotide conversion sequencing reads with HISAT-3N. Genome Res. 2021;31:1290\u20135.","journal-title":"Genome Res"},{"issue":"6","key":"484_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1009730","volume":"18","author":"A Shumate","year":"2022","unstructured":"Shumate A, Wong B, Pertea G, Pertea M. Improved transcriptome assembly using a hybrid of long and short reads with StringTie. Plos Comput Biol. 2022;18(6): e1009730.","journal-title":"Plos Comput Biol"},{"issue":"1","key":"484_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","volume":"21","author":"VC Jiang","year":"2022","unstructured":"Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y, et al. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer. 2022;21(1):185.","journal-title":"Mol Cancer"},{"issue":"Suppl 1","key":"484_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2020-137473","volume":"136","author":"P Jain","year":"2020","unstructured":"Jain P, Tang GL, Yin CC, Ok CY, Navsaria L, Badillo M, et al. Complex karyotype is a significant predictor for worst outcomes in patients with mantle cell lymphoma (MCL) treated with BTK Inhibitors - comprehensive analysis of 396 patients. Blood. 2020;136(Suppl 1):32\u20133.","journal-title":"Blood"},{"issue":"6","key":"484_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325.","journal-title":"Cell Syst"},{"issue":"2","key":"484_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/21541264.2018.1523668","volume":"10","author":"CW Bacon","year":"2019","unstructured":"Bacon CW, D\u2019Orso I. CDK9: a signaling hub for transcriptional control. Transcription. 2019;10(2):57\u201375.","journal-title":"Transcription"},{"issue":"10","key":"484_CR29","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nmeth.3971","volume":"13","author":"L Haghverdi","year":"2016","unstructured":"Haghverdi L, Buttner M, Wolf FA, Buettner F, Theis FJ. Diffusion pseudotime robustly reconstructs lineage branching. Nat Methods. 2016;13(10):845\u20138.","journal-title":"Nat Methods"},{"issue":"8","key":"484_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00439-016-1683-5","volume":"135","author":"T Geuens","year":"2016","unstructured":"Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and disease. Hum Genet. 2016;135(8):851\u201367.","journal-title":"Hum Genet"},{"issue":"10","key":"484_CR31","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/onc.2012.144","volume":"32","author":"I Paul","year":"2013","unstructured":"Paul I, Ahmed SF, Bhowmik A, Deb S, Ghosh MK. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene. 2013;32(10):1284\u201395.","journal-title":"Oncogene"},{"issue":"16","key":"484_CR32","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1182\/bloodadvances.2018016048","volume":"2","author":"J Lee","year":"2018","unstructured":"Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, et al. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018;2(16):2039\u201351.","journal-title":"Blood Adv"},{"issue":"1","key":"484_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","volume":"19","author":"A Huang","year":"2020","unstructured":"Huang A, Garraway LA, Ashworth A, Weber B. Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov. 2020;19(1):23\u201338.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"484_CR34","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1038\/s41467-019-11552-8","volume":"10","author":"W Miao","year":"2019","unstructured":"Miao W, Li L, Zhao Y, Dai X, Chen X, Wang Y. HSP90 inhibitors stimulate DNAJB4 protein expression through a mechanism involving N(6)-methyladenosine. Nat Commun. 2019;10(1):3613.","journal-title":"Nat Commun"},{"issue":"1","key":"484_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19(1):23\u201336.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"484_CR36","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3324\/haematol.2019.243071","volume":"106","author":"L Wang","year":"2021","unstructured":"Wang L, Tang G, Medeiros LJ, Xu J, Huang W, Yin CC, et al. MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica. 2021;106(5):1381\u20139.","journal-title":"Haematologica"},{"issue":"24","key":"484_CR37","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1182\/blood-2013-05-498329","volume":"122","author":"G Ott","year":"2013","unstructured":"Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122(24):3884\u201391.","journal-title":"Blood"},{"issue":"22","key":"484_CR38","doi-asserted-by":"publisher","first-page":"7046","DOI":"10.1073\/pnas.81.22.7046","volume":"81","author":"C Dani","year":"1984","unstructured":"Dani C, Blanchard JM, Piechaczyk M, El Sabouty S, Marty L, Jeanteur P. Extreme instability of myc mRNA in normal and transformed human cells. Proc Natl Acad Sci USA. 1984;81(22):7046\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"484_CR39","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1128\/MCB.20.7.2423-2435.2000","volume":"20","author":"MA Gregory","year":"2000","unstructured":"Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt\u2019s lymphoma cells. Mol Cell Biol. 2000;20(7):2423\u201335.","journal-title":"Mol Cell Biol"},{"key":"484_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","volume":"3","author":"H Chen","year":"2018","unstructured":"Chen H, Liu HD, Qing GL. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3:5.","journal-title":"Signal Transduct Target Ther"},{"issue":"Suppl 1","key":"484_CR41","first-page":"34","volume":"136","author":"M Wang","year":"2020","unstructured":"Wang M, Zhao XH, Jiang HJ, Yan JC, Sotomayor E, Shain KH, et al. CDK9 as a new therapeutic vulnerability for ibrutinib resistance in mantle cell lymphoma (MCL). Blood. 2020;136(Suppl 1):34\u20135.","journal-title":"Blood"},{"issue":"11","key":"484_CR42","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/cancers10110448","volume":"10","author":"CJ Poole","year":"2018","unstructured":"Poole CJ, Zheng W, Lee H, Young D, Lodh A, Chadli A, et al. Targeting the MYC oncogene in Burkitt lymphoma through HSP90 inhibition. Cancers (Basel). 2018;10(11):448.","journal-title":"Cancers (Basel)"},{"issue":"21","key":"484_CR43","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1182\/blood-2016-04-711176","volume":"128","author":"C Jacobson","year":"2016","unstructured":"Jacobson C, Kopp N, Layer JV, Redd RA, Tschuri S, Haebe S, et al. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood. 2016;128(21):2517\u201326.","journal-title":"Blood"},{"issue":"1","key":"484_CR44","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1038\/s41467-019-11552-8","volume":"10","author":"W Miao","year":"2019","unstructured":"Miao W, Li L, Zhao Y, Dai X, Chen X, Wang Y. HSP90 inhibitors stimulate DNAJB4 protein expression through a mechanism involving N6-methyladenosine. Nat Commun. 2019;10(1):3613.","journal-title":"Nat Commun"}],"updated-by":[{"DOI":"10.1186\/s40164-025-00735-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000}}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-024-00484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-024-00484-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-024-00484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:02:36Z","timestamp":1770786156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-024-00484-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1186\/s40164-024-00484-9","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"assertion":[{"value":"9 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40164-025-00735-3","URL":"https:\/\/doi.org\/10.1186\/s40164-025-00735-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patient samples were collected after obtaining written informed consent and approval from the Institutional Review Board at The University of Texas MD Anderson Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MW is consultant to AstraZeneca, BeiGene, BioInvent, CSTone, Deciphera, DTRM Biopharma (Cayman) Limited, Epizyme, Genentech, InnoCare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Miltenyi Biomedicine GmbH, Oncternal, Pepromene Bio, Pharmacyclics, VelosBio. MW has received research support from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genmab, Genentech, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio, Vincerx. MW received a speaker honoraria from Acerta Pharma, Anticancer Association, AstraZeneca, BeiGene, BGICS, BioInvent, CAHON, Clinical Care Options, Dava Oncology, Eastern Virginia Medical School, Epizyme, Hebei Cancer Prevention Federation, Imedex, Janssen, Kite Pharma, Leukemia & Lymphoma Society, LLC TS Oncology, Medscape, Meeting Minds Experts, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, OMI, OncLive, Pharmacyclics,\u00a0Physicians Education Resources (PER), Practice Point Communications (PPC), The First Afflicted Hospital of Zhejiang University. ZZ is a consultant of Melax.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}